You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA705
  • Published:  02 June 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 145 KB)

    Published:
    02 June 2021
  • Register of interests (PDF 142 KB)

    Published:
    02 June 2021

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 199 KB)

    Published:
    22 April 2021
  • Public committee slides (PDF 484 KB)

    Published:
    22 April 2021
  • Committee papers (PDF 2.97 MB)

    Published:
    22 April 2021

Invitation to participate

  • Final scope (PDF 256 KB)

    Published:
    03 April 2020
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 183 KB)

    Published:
    03 April 2020
  • Final stakeholder list (PDF 212 KB)

    Published:
    03 April 2020
  • Equality impact assessment (Scoping) (PDF 121 KB)

    Published:
    03 April 2020

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft scope post referral (PDF 271 KB)

    Published:
    14 January 2020
  • Draft matrix post referral (PDF 212 KB)

    Published:
    14 January 2020
Back to top